Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipifarnib Post-Consolidation in Elderly AML
NCT00048503Phase 2Completed
- Sponsor
- Johnson & Johnson
- Start
- Jun 2002
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of tipifarnib in acute myeloid leukemia (AML), sponsored by Johnson & Johnson. Started Jun 2002; status: completed.
02
Drugs
tipifarnib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00048503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00048503.